Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

560 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial).
Mercado N, Brugts JJ, Ix JH, Shlipak MG, Dixon SR, Gersh BJ, Lemos PA, Guarneri M, Teirstein PS, Wijns W, Serruys PW, Boersma E, O'Neill WW. Mercado N, et al. Am J Cardiol. 2008 Nov 1;102(9):1151-5. doi: 10.1016/j.amjcard.2008.06.035. Epub 2008 Aug 9. Am J Cardiol. 2008. PMID: 18940282 Clinical Trial.
One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials.
Mercado N, Wijns W, Serruys PW, Sigwart U, Flather MD, Stables RH, O'Neill WW, Rodriguez A, Lemos PA, Hueb WA, Gersh BJ, Booth J, Boersma E. Mercado N, et al. J Thorac Cardiovasc Surg. 2005 Aug;130(2):512-9. doi: 10.1016/j.jtcvs.2004.12.049. J Thorac Cardiovasc Surg. 2005. PMID: 16077421 Free article.
Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial).
Brugts JJ, Mercado N, Hu S, Guarneri M, Price M, Schatz R, Teirstein P, Wijns W, Serruys PW, O'Neill WW, Boersma E. Brugts JJ, et al. Am J Cardiol. 2009 Apr 1;103(7):917-22. doi: 10.1016/j.amjcard.2008.12.017. Epub 2009 Feb 7. Am J Cardiol. 2009. PMID: 19327416 Clinical Trial.
Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.
Camenzind E, Wijns W, Mauri L, Boersma E, Parikh K, Kurowski V, Gao R, Bode C, Greenwood JP, Gershlick A, O'Neill W, Serruys PW, Jorissen B, Steg PG; PROTECT Steering Committee and Investigators. Camenzind E, et al. Am Heart J. 2009 Dec;158(6):902-909.e5. doi: 10.1016/j.ahj.2009.10.002. Am Heart J. 2009. PMID: 19958855 Clinical Trial.
Fibrinolytic therapy: is it a treatment of the past?
Grines CL, Serruys P, O'Neill WW. Grines CL, et al. Circulation. 2003 May 27;107(20):2538-42. doi: 10.1161/01.CIR.0000075292.29458.BB. Circulation. 2003. PMID: 12777318 Review. No abstract available.
560 results